Keith C. Deen

6.5k total citations · 3 hit papers
37 papers, 3.6k citations indexed

About

Keith C. Deen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Keith C. Deen has authored 37 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology. Recurrent topics in Keith C. Deen's work include Renal cell carcinoma treatment (13 papers), HIV Research and Treatment (7 papers) and Economic and Financial Impacts of Cancer (6 papers). Keith C. Deen is often cited by papers focused on Renal cell carcinoma treatment (13 papers), HIV Research and Treatment (7 papers) and Economic and Financial Impacts of Cancer (6 papers). Keith C. Deen collaborates with scholars based in United States, United Kingdom and Australia. Keith C. Deen's co-authors include Raymond W. Sweet, Paul J. Maddon, Carol Silverman, Alemseged Truneh, J. Steven McDougal, Sally D. Lyn, Peter McDonnell, Peter R. Young, John G. Emery and Richard Axel and has published in prestigious journals such as Nature, Cell and Nucleic Acids Research.

In The Last Decade

Keith C. Deen

37 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

1998 989 citations John G. Emery, Peter McDonnell et al. Journal of Biological Chemistry profile →
soluble form of CD4 (T4) protein inhibits AIDS virus infection

1988 460 citations Keith C. Deen, J. Steven McDougal et al. Nature profile →
Identification of the residues in human CD4 critical for the binding of HIV

1989 320 citations James Arthos, Keith C. Deen et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith C. Deen United States	20	1.7k	1.5k	1.0k	750	508	37	3.6k
Jean Plum Belgium	41	1.7k 1.0×	2.5k 1.7×	926 0.9×	903 1.2×	269 0.5×	168	5.3k
Jens Dhein Germany	13	2.6k 1.5×	2.5k 1.7×	756 0.8×	867 1.2×	562 1.1×	24	4.8k
Avi Ashkenazi United States	26	2.3k 1.3×	2.4k 1.7×	465 0.5×	761 1.0×	813 1.6×	37	4.3k
E. Peter Rieber Germany	29	1.1k 0.6×	2.9k 2.0×	1.9k 1.8×	630 0.8×	180 0.4×	70	4.6k
L Osborn United States	17	1.1k 0.7×	1.6k 1.1×	479 0.5×	385 0.5×	638 1.3×	21	3.6k
Cecilia Sgadari Italy	29	1.3k 0.7×	1.6k 1.1×	464 0.5×	2.2k 2.9×	312 0.6×	68	4.2k
Wolf K. Hofmann Germany	20	1.8k 1.0×	621 0.4×	849 0.8×	459 0.6×	483 1.0×	41	3.4k
John C. Castle United States	15	1.2k 0.7×	1.5k 1.0×	352 0.3×	1.2k 1.7×	212 0.4×	21	2.8k
Andreas S. Baur Germany	29	1.3k 0.7×	1.3k 0.9×	1.9k 1.9×	244 0.3×	252 0.5×	61	3.3k
Josef Cihak Germany	23	900 0.5×	1.9k 1.3×	329 0.3×	663 0.9×	152 0.3×	44	3.1k

Countries citing papers authored by Keith C. Deen

Since Specialization

Citations

This map shows the geographic impact of Keith C. Deen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith C. Deen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith C. Deen more than expected).

Fields of papers citing papers by Keith C. Deen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith C. Deen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith C. Deen. The network helps show where Keith C. Deen may publish in the future.

Co-authorship network of co-authors of Keith C. Deen

This figure shows the co-authorship network connecting the top 25 collaborators of Keith C. Deen. A scholar is included among the top collaborators of Keith C. Deen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith C. Deen. Keith C. Deen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Chun‐Fang, Toby Johnson, Jesús García-Donás, et al.. (2015). IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer. 112(7). 1190–1198. 28 indexed citations

Choueiri, Toni K., David J. Figueroa, André P. Fay, et al.. (2014). Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research. 21(5). 1071–1077. 187 indexed citations

Hackshaw, Michelle D., Ryan N. Hansen, Saurabh Nagar, et al.. (2014). Costs Associated with Health Care Resource Use in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Treatment with Pazopanib Versus Sunitinib. Value in Health. 17(3). A77–A78. 1 indexed citations

Sternberg, Cora N., et al.. (2014). An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma. Oncology. 87(6). 342–350. 9 indexed citations

Motzer, Robert J., Thomas E. Hutson, James A. Reeves, et al.. (2012). Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial. Annals of Oncology. 23. ixe13–ixe13. 57 indexed citations

Holmes, Steve, Angela M. Downs, Andrew Fosberry, et al.. (2002). Sema7A is a Potent Monocyte Stimulator. Scandinavian Journal of Immunology. 56(3). 270–275. 131 indexed citations

Li, Jian, Patricia Van Belle, Ping Tsui, et al.. (2001). Isolation of the Melanoma-Associated Antigen p23 Using Antibody Phage Display. The Journal of Immunology. 166(1). 432–438. 15 indexed citations

Morel, Yannis, Jean‐Marc Schiano de Colella, Keith C. Deen, et al.. (2000). Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor. The Journal of Immunology. 165(8). 4397–4404. 143 indexed citations

Esser, Ursula, Roberto F. Speck, Keith C. Deen, et al.. (2000). Molecular Function of the CD4 D1 Domain in Coreceptor-Mediated Entry by HIV Type 1. AIDS Research and Human Retroviruses. 16(17). 1845–1854. 13 indexed citations

10.

Harrison, David C., Jenny C. Roberts, C. A. Campbell, et al.. (2000). TR3 death receptor expression in the normal and ischaemic brain. Neuroscience. 96(1). 147–160. 25 indexed citations

11.

Truneh, Alemseged, Sunita Sharma, Carol Silverman, et al.. (2000). Temperature-sensitive Differential Affinity of TRAIL for Its Receptors. Journal of Biological Chemistry. 275(30). 23319–23325. 214 indexed citations

12.

Emery, John G., Peter McDonnell, Keith C. Deen, et al.. (1998). Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL. Journal of Biological Chemistry. 273(23). 14363–14367. 989 indexed citations breakdown →

13.

McDonnell, Peter, Michael Brigham‐Burke, Sally D. Lyn, et al.. (1998). Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth. Journal of Biological Chemistry. 273(42). 27548–27556. 196 indexed citations

14.

Ames, Robert S., Mark Tornetta, Keith C. Deen, et al.. (1995). Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. Journal of Immunological Methods. 184(2). 177–186. 26 indexed citations

15.

Arthos, James, Keith C. Deen, Quentin J. Sattentau, et al.. (1990). STRUCTURAL-ANALYSIS OF THE HIV GP120 BINDING DOMAIN OF THE CD4 RECEPTOR. AIDS Research and Human Retroviruses. 6. 118–118. 2 indexed citations

16.

Arthos, James, et al.. (1990). The Genetic Analysis of the HIV Envelope Binding Domain on CD4. Annals of the New York Academy of Sciences. 616(1). 116–124. 5 indexed citations

17.

Sattentau, Quentin J., James Arthos, Keith C. Deen, et al.. (1989). Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes.. The Journal of Experimental Medicine. 170(4). 1319–1334. 126 indexed citations

18.

Clapham, Paul R., Jonathan Weber, Denise Whitby, et al.. (1989). Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature. 337(6205). 368–370. 339 indexed citations

19.

Arthos, James, Keith C. Deen, Margery A. Chaikin, et al.. (1989). Identification of the residues in human CD4 critical for the binding of HIV. Cell. 57(3). 469–481. 320 indexed citations breakdown →

20.

Deen, Keith C., J. Steven McDougal, Gail Folena-Wasserman, et al.. (1988). soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 331(6151). 82–84. 460 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact